UA105211C2 - Хиноксалиновые производные и их применение для лечения доброкачественных и злокачественных опухолевых заболеваний - Google Patents

Хиноксалиновые производные и их применение для лечения доброкачественных и злокачественных опухолевых заболеваний

Info

Publication number
UA105211C2
UA105211C2 UAA201111539A UAA201111539A UA105211C2 UA 105211 C2 UA105211 C2 UA 105211C2 UA A201111539 A UAA201111539 A UA A201111539A UA A201111539 A UAA201111539 A UA A201111539A UA 105211 C2 UA105211 C2 UA 105211C2
Authority
UA
Ukraine
Prior art keywords
tumour disorders
malignant tumour
quinoxaline derivatives
treating benign
disorders
Prior art date
Application number
UAA201111539A
Other languages
English (en)
Ukrainian (uk)
Inventor
Маттиас ГЕРЛАХ
Ирэна Зейпелт
Экхард ГЮНТЕР
Тильманн ШУСТЕР
Эммануэль Полимеропоулос
Михаель Чех
Экхард КЛАУС
Original Assignee
Аэтерна Центарис Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аэтерна Центарис Гмбх filed Critical Аэтерна Центарис Гмбх
Publication of UA105211C2 publication Critical patent/UA105211C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Согласно этому изобретению предложенные хиноксалины общей формулы I, которые применяются как лекарственные средства для лечения опухолевых заболеваний, в частности в случаях резистентности к другим активных соединений или в случаях карциномы, которая метастазирует.Возможные области применения не ограничиваются опухолевыми заболеваниями.Формула I
UAA201111539A 2009-04-02 2010-03-25 Хиноксалиновые производные и их применение для лечения доброкачественных и злокачественных опухолевых заболеваний UA105211C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09157141A EP2241557A1 (de) 2009-04-02 2009-04-02 Chinoxalin-Derivate und deren Anwendung zur Behandlung gutartiger und bösartiger Tumorerkrankungen
PCT/EP2010/053891 WO2010115719A1 (en) 2009-04-02 2010-03-25 Quinoxaline derivatives and their use for treating benign and malignant tumour disorders

Publications (1)

Publication Number Publication Date
UA105211C2 true UA105211C2 (ru) 2014-04-25

Family

ID=40886691

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201111539A UA105211C2 (ru) 2009-04-02 2010-03-25 Хиноксалиновые производные и их применение для лечения доброкачественных и злокачественных опухолевых заболеваний

Country Status (20)

Country Link
US (1) US8394801B2 (ru)
EP (2) EP2241557A1 (ru)
JP (1) JP5583201B2 (ru)
KR (1) KR20110136888A (ru)
CN (1) CN102378758A (ru)
AR (1) AR075935A1 (ru)
AU (1) AU2010233983A1 (ru)
BR (1) BRPI1010306A2 (ru)
CA (1) CA2757138A1 (ru)
CO (1) CO6501171A2 (ru)
EC (1) ECSP11011363A (ru)
IL (1) IL215025A0 (ru)
MX (1) MX2011010329A (ru)
NZ (1) NZ595064A (ru)
PE (1) PE20120766A1 (ru)
RU (1) RU2532914C2 (ru)
SG (1) SG175014A1 (ru)
TW (1) TWI464150B (ru)
UA (1) UA105211C2 (ru)
WO (1) WO2010115719A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464675A (zh) * 2010-11-12 2012-05-23 上海医药工业研究院 具有抗肿瘤活性的金络合物及其可药用衍生物
WO2013013816A1 (en) 2011-07-26 2013-01-31 Grünenthal GmbH Substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands
CN108137514A (zh) * 2015-07-30 2018-06-08 百时美施贵宝公司 芳基取代的二环杂芳基化合物
EP3464270B1 (en) * 2016-05-24 2022-02-23 Genentech, Inc. Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
CN110698418B (zh) * 2019-09-11 2022-07-01 广西师范大学 一种3-芳胺基喹喔啉-2-甲酰胺类衍生物及其制备方法和应用
CN115463217B (zh) * 2021-06-11 2024-03-12 深圳埃格林医药有限公司 己酸羟孕酮在增强肿瘤治疗效果中的应用
CN114605391B (zh) * 2022-02-21 2024-01-26 广州六顺生物科技股份有限公司 喹喔啉类衍生物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN842196A0 (en) 1996-03-05 1996-03-28 Fujisawa Pharmaceutical Co., Ltd. New compound
US6245760B1 (en) 1997-05-28 2001-06-12 Aventis Pharmaceuticals Products, Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6180632B1 (en) 1997-05-28 2001-01-30 Aventis Pharmaceuticals Products Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6159978A (en) 1997-05-28 2000-12-12 Aventis Pharmaceuticals Product, Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
SI0991628T1 (en) 1997-05-28 2005-06-30 Aventis Pharmaceuticals Inc QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES
KR20010043981A (ko) 1998-06-01 2001-05-25 시오노 요시히코 시아노이미노퀴녹살린 유도체
UA76977C2 (en) * 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
US7202244B2 (en) * 2002-05-29 2007-04-10 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
US20070254894A1 (en) 2006-01-10 2007-11-01 Kane John L Jr Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
WO2008015423A1 (en) 2006-08-01 2008-02-07 Sentinel Oncology Limited Quinoline and quinoxaline n-oxides as chk-1 inhibitors
EP1990342A1 (en) * 2007-05-10 2008-11-12 AEterna Zentaris GmbH Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
PE20090288A1 (es) 2007-05-10 2009-04-03 Smithkline Beecham Corp Derivados de quinoxalina como inhibidores de la pi3 quinasa

Also Published As

Publication number Publication date
AR075935A1 (es) 2011-05-04
EP2241557A1 (de) 2010-10-20
ECSP11011363A (es) 2011-10-31
US20100266538A1 (en) 2010-10-21
US8394801B2 (en) 2013-03-12
MX2011010329A (es) 2011-10-17
CA2757138A1 (en) 2010-10-14
RU2011138477A (ru) 2013-05-10
CO6501171A2 (es) 2012-08-15
TW201100391A (en) 2011-01-01
KR20110136888A (ko) 2011-12-21
RU2532914C2 (ru) 2014-11-20
TWI464150B (zh) 2014-12-11
WO2010115719A1 (en) 2010-10-14
PE20120766A1 (es) 2012-07-19
IL215025A0 (en) 2011-11-30
EP2419411A1 (en) 2012-02-22
NZ595064A (en) 2013-10-25
AU2010233983A1 (en) 2011-10-06
JP2012522741A (ja) 2012-09-27
CN102378758A (zh) 2012-03-14
BRPI1010306A2 (pt) 2017-05-16
JP5583201B2 (ja) 2014-09-03
SG175014A1 (en) 2011-11-28

Similar Documents

Publication Publication Date Title
EA023222B8 (ru) Пиразолилхиноксалиновые ингибиторы киназы
UA105211C2 (ru) Хиноксалиновые производные и их применение для лечения доброкачественных и злокачественных опухолевых заболеваний
PH12012500497A1 (en) Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
PH12013500299B1 (en) Pyrrolopyrimidine compounds and uses thereof
PH12017502141A1 (en) Compounds and their methods of use
PH12013501600A1 (en) Novel heterocyclic derivatives
MX2014004861A (es) Benzopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr).
GEP201706691B (en) Substituted phthalazin-1 (2h)-one derivatives as selecti- ve inhibitors of poly (adp-ribose) polymerase-1
UA112795C2 (uk) Біциклічні піразинонові похідні
MX357502B (es) Derivados de pirrolotriazinona.
BR112013008523A2 (pt) compostos de piridazina carboxamida substituídos
MX336761B (es) Compuestos para el tratamiento de cancer.
MX2018003563A (es) Nuevos compuestos.
NZ702253A (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
IN2015DN01328A (ru)
BR112013009260A2 (pt) compostos de carboxamida de piridazina substituídos como compostos inibidores de quinase
MX2011006532A (es) Compuestos anticancerigenos.
TW200621270A (en) Novel use of nanogold for manufacturing medicaments for inhibiting metastasis of malignant tumors and growth of leukemic cells, and pharmaceutical compositions for inhibiting metastasis of malignant tumors and for treating leukemia comprising nanogold
GB2519004A (en) Quinone compounds and their uses for the treatment of cancer
AU2015373422A8 (en) New imidazo[1,2-a]quinoxalines and derivates thereof for the treatment of cancer
TN2013000327A1 (en) Novel heterocyclic derivatives
EP2575766A4 (en) NEW PHARMACEUTICAL COMPOUNDS
UA110793C2 (uk) Піразолілхіноксалінові інгібітори кінази
MX2017007648A (es) Composicion farmaceutica que comprende compuesto biciclico de amida heterociclica aromatica que contiene nitrogeno como ingrediente activo.